Table 5.
Adverse events in the Hispanic and Non-Hispanic population through week 52
| Variablea | Hispanic subgroup | Non-Hispanic subgroup | ||||
|---|---|---|---|---|---|---|
| Secukinumab 300 mg (n = 88) | Secukinumab 150 mg (n = 97) | Etanercept (n = 51) | Secukinumab 300 mg (n = 602) | Secukinumab 150 mg (n = 595) | Etanercept (n = 272) | |
| Mean exposure to study treatment (days ± SD) | 333.7 ± 90.4 | 338.5 ± 80.9 | 329.0 ± 98.0 | 344.8 ± 69.9 | 336.2 ± 80.0 | 332.5 ± 88.2 |
| Serious adverse event | 2 (2.3) | 4 (4.1) | 2 (3.9) | 46 (7.6) | 44 (7.4) | 18 (6.6) |
| Any adverse event | 70 (79.5) | 78 (80.4) | 42 (82.4) | 505 (83.9) | 484 (81.3) | 211 (77.6) |
| Discontinuations because of adverse events | 4 (4.5) | 4 (4.1) | 2 (3.9) | 17 (2.8) | 21 (3.5) | 10 (3.7) |
| Most common adverse events | ||||||
| Headache | 15 (17.0) | 11 (11.3) | 10 (19.6) | 64 (10.6) | 54 (9.1) | 30 (11.0) |
| Nasopharyngitis | 14 (15.9) | 11 (11.3) | 4 (7.8) | 158 (26.2) | 153 (25.7) | 82 (30.1) |
| Diarrhea | 12 (13.6) | 10 (10.3) | 3 (5.9) | 42 (7.0) | 35 (5.9) | 19 (7.0) |
| Influenza | 11 (12.5) | 15 (15.5) | 4 (7.8) | 16 (2.7) | 11 (1.8) | 7 (2.6) |
| Pharyngitis | 9 (10.2) | 5 (5.2) | 3 (5.9) | 9 (1.5) | 14 (2.4) | 3 (1.1) |
| Upper respiratory tract infection | 5 (5.7) | 8 (8.2) | 2 (3.9) | 48 (8.0) | 56 (9.4) | 16 (5.9) |
Adverse events that occurred in >5% of patients from both the Hispanic and non-Hispanic secukinumab treatment subgroups were included. Most common adverse events are sorted in descending order of frequency for the Hispanic secukinumab 300-mg subgroup
SD standard deviation
a n (%) unless otherwise noted